Immunity, inflammation and disease · 2021
SLy2-overexpression impairs B-cell development in the bone marrow and the IgG response towards pneumococcal conjugate-vaccine.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jaufmann Jennifer, Tümen Leyla, Beer-Hammer Sandra
Аннотация
BACKGROUND: Infections with Streptococcus pneumoniae can cause severe diseases in humans including pneumonia. Although guidelines for vaccination have been established, S. pneumoniae is still responsible for a serious burden of disease around the globe. Currently, two pneumococcal immunizations are available, namely the pure polysaccharide vaccine Pneumovax23 (P23) and the conjugate-vaccine Prevenar13 (PCV13). We recently reported impaired thymus-independent antibody responses towards P23 in mice overexpressing the immunoinhibitory adapter SLy2. The purpose of this study was to evaluate adaptive B-cell responses towards the thymus-dependent vaccine PCV13 in SLy2-overexpressing mice and to study their survival rate during pneumococcal lung infection. Moreover, we investigated B-cell developmental stages within the bone marrow (BM) in the context of excessive SLy2-expression.
METHODS: B-cell subsets and their surface immune globulins were investigated by flow cytometry. For class-switch assays, isolated splenic B cells were stimulated in vitro with lipopolysaccharide and interleukin-4 and antibody secretion was quantified via LEGENDplex. To study PCV13-specific responses, mice were immunized and serum antibody titers (immunoglobulin M, immunoglobulins IgG1 , IgG2 , and IgG3 ) were examined by enzyme-linked immunosorbent assay. Survival rates of mice were assessed within 7 days upon intranasal challenge with S. pneumoniae.
RESULTS: Our data demonstrate impaired IgG1 and IgG3 antibody responses towards the pneumococcal conjugate-vaccine PCV13 in SLy2-overexpressing mice. This was accompanied by reduced frequencies and numbers of BM-resident plasmablasts. In addition, we found drastically reduced counts of B-cell precursors in the BM of SLy2-Tg mice. The survival rate upon intranasal challenge with S. pneumoniae was mostly comparable between the genotypes.
CONCLUSION: Our findings demonstrate an important role of the adapter protein SLy2 in the context of adaptive antibody responses against pneumococcal conjugate-vaccine. Interestingly, deficits in humoral immunity seemed to be compensated by cellular immune effectors upon bacterial challenge. Our study further shows a novel relevance of SLy2 for plasmablasts and B-cell progenitors in the BM.
METHODS: B-cell subsets and their surface immune globulins were investigated by flow cytometry. For class-switch assays, isolated splenic B cells were stimulated in vitro with lipopolysaccharide and interleukin-4 and antibody secretion was quantified via LEGENDplex. To study PCV13-specific responses, mice were immunized and serum antibody titers (immunoglobulin M, immunoglobulins IgG1 , IgG2 , and IgG3 ) were examined by enzyme-linked immunosorbent assay. Survival rates of mice were assessed within 7 days upon intranasal challenge with S. pneumoniae.
RESULTS: Our data demonstrate impaired IgG1 and IgG3 antibody responses towards the pneumococcal conjugate-vaccine PCV13 in SLy2-overexpressing mice. This was accompanied by reduced frequencies and numbers of BM-resident plasmablasts. In addition, we found drastically reduced counts of B-cell precursors in the BM of SLy2-Tg mice. The survival rate upon intranasal challenge with S. pneumoniae was mostly comparable between the genotypes.
CONCLUSION: Our findings demonstrate an important role of the adapter protein SLy2 in the context of adaptive antibody responses against pneumococcal conjugate-vaccine. Interestingly, deficits in humoral immunity seemed to be compensated by cellular immune effectors upon bacterial challenge. Our study further shows a novel relevance of SLy2 for plasmablasts and B-cell progenitors in the BM.